The article offers information on the Daratumumab (DARA), a first in class anti-CD38 human
antibody (IgG1j) with efficacy in relapsed multiple myeloma (MM) as monotherapy and in …

The IMPEDE VTE score has recently emerged as a novel risk prediction tool for venous
thromboembolism (VTE) in multiple myeloma (MM). We retrospectively reviewed 839 patients …

Although venous thromboembolism (VTE) is an important treatment and disease-related
complication in myeloma, a validated risk prediction model including disease-specific variables …

… Danai Dima, Ang Li, Lauren M Granat, Puneet Dhillon, Fatima Chamseddine, Anirudh
Yalamanchali, Saeid Mirzai, Wei Wei, Christy J. Samaras and Jack Khouri have no conflicts of …

… Samaras… Faiman, Christy J. Samaras, Nathaniel Rosko, and Jason Valent provided
critical input in study design, analysis and manuscript writing and approved the final draft. …

Dear Editor, Although the incidence and risk factors of venous thromboembolism [VTE] is
well characterized in multiple myeloma [MM], little is known regarding the characterization of …

Background: CAEL-101 is an AL amyloid fibril reactive IgG1 monoclonal antibody with potential
for therapeutic immune clearance of AL amyloid deposits in AL amyloidosis (AL) patients…

Response rate and survival in multiple myeloma (MM) has improved in the era of proteasome
inhibitors and immunomodulatory drugs. However, most patients eventually relapse with …

Cardiac amyloidosis results in an infiltrative restrictive cardiomyopathy, with a number of
characteristic features: biventricular hypertrophy, abnormal myocardial global longitudinal strain …

Introduction: Lenalidomide (LEN), a standard of care for newly diagnosed multiple myeloma,
is routinely administered until disease progression. However, patients with disease that has …